» Articles » PMID: 32817306

Iron-responsive-like Elements and Neurodegenerative Ferroptosis

Overview
Journal Learn Mem
Specialty Neurology
Date 2020 Aug 21
PMID 32817306
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

A set of common-acting iron-responsive 5'untranslated region (5'UTR) motifs can fold into RNA stem loops that appear significant to the biology of cognitive declines of Parkinson's disease dementia (PDD), Lewy body dementia (LDD), and Alzheimer's disease (AD). Neurodegenerative diseases exhibit perturbations of iron homeostasis in defined brain subregions over characteristic time intervals of progression. While misfolding of Aβ from the amyloid-precursor-protein (APP), alpha-synuclein, prion protein (PrP) each cause neuropathic protein inclusions in the brain subregions, iron-responsive-like element (IRE-like) RNA stem-loops reside in their transcripts. APP and αsyn have a role in iron transport while gene duplications elevate the expression of their products to cause rare familial cases of AD and PDD. Of note, IRE-like sequences are responsive to excesses of brain iron in a potential feedback loop to accelerate neuronal ferroptosis and cognitive declines as well as amyloidosis. This pathogenic feedback is consistent with the translational control of the iron storage protein ferritin. We discuss how the IRE-like RNA motifs in the 5'UTRs of APP, alpha-synuclein and PrP mRNAs represent uniquely folded drug targets for therapies to prevent perturbed iron homeostasis that accelerates AD, PD, PD dementia (PDD) and Lewy body dementia, thus preventing cognitive deficits. Inhibition of alpha-synuclein translation is an option to block manganese toxicity associated with early childhood cognitive problems and manganism while Pb toxicity is epigenetically associated with attention deficit and later-stage AD. Pathologies of heavy metal toxicity centered on an embargo of iron export may be treated with activators of APP and ferritin and inhibitors of alpha-synuclein translation.

Citing Articles

Genetic Markers of Postmortem Brain Iron.

Cornelis M, Fazlollahi A, Bennett D, Schneider J, Ayton S J Neurochem. 2025; 169(2):e16309.

PMID: 39918201 PMC: 11804167. DOI: 10.1111/jnc.16309.


Targeting Iron Responsive Elements (IREs) of APP mRNA into Novel Therapeutics to Control the Translation of Amyloid-β Precursor Protein in Alzheimer's Disease.

Khan M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770511 PMC: 11677800. DOI: 10.3390/ph17121669.


The Underestimated Role of Iron in Frontotemporal Dementia: A Narrative Review.

Ferretti S, Zanella I Int J Mol Sci. 2024; 25(23).

PMID: 39684697 PMC: 11640923. DOI: 10.3390/ijms252312987.


Neuroprotective Strategies and Cell-Based Biomarkers for Manganese-Induced Toxicity in Human Neuroblastoma (SH-SY5Y) Cells.

Cahill C, Sarang S, Bakshi R, Xia N, Lahiri D, Rogers J Biomolecules. 2024; 14(6).

PMID: 38927051 PMC: 11201412. DOI: 10.3390/biom14060647.


The Iron Metabolism with a Specific Focus on the Functioning of the Nervous System.

Kulaszynska M, Kwiatkowski S, Skonieczna-Zydecka K Biomedicines. 2024; 12(3).

PMID: 38540208 PMC: 10968467. DOI: 10.3390/biomedicines12030595.


References
1.
Singh N, Haldar S, Tripathi A, McElwee M, Horback K, Beserra A . Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease. Antioxid Redox Signal. 2014; 21(3):471-84. PMC: 4076993. DOI: 10.1089/ars.2014.5874. View

2.
Wirbisky S, Weber G, Lee J, Cannon J, Freeman J . Novel dose-dependent alterations in excitatory GABA during embryonic development associated with lead (Pb) neurotoxicity. Toxicol Lett. 2014; 229(1):1-8. PMC: 4109047. DOI: 10.1016/j.toxlet.2014.05.016. View

3.
Haining R, Achat-Mendes C . Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator. Neural Regen Res. 2017; 12(3):372-375. PMC: 5399705. DOI: 10.4103/1673-5374.202928. View

4.
Chiou B, Neely E, McDevitt D, Simpson I, Connor J . Transferrin and H-ferritin involvement in brain iron acquisition during postnatal development: impact of sex and genotype. J Neurochem. 2019; 152(3):381-396. PMC: 6980902. DOI: 10.1111/jnc.14834. View

5.
Walker Z, Possin K, Boeve B, Aarsland D . Lewy body dementias. Lancet. 2015; 386(10004):1683-97. PMC: 5792067. DOI: 10.1016/S0140-6736(15)00462-6. View